CHM 11.1% 2.0¢ chimeric therapeutics limited

How important is this statement. L1 Capital has completed,...

  1. 409 Posts.
    lightbulb Created with Sketch. 744
    How important is this statement. L1 Capital has completed, (SIGNIFICANT DUE DILIGENCE VIA THEIR SPECIALIST MEDICAL CONSULTANT)
    PRIOR TO EXECUTING THE PLACEMENT AGREEMENT.
    They have confidence in what CHM have, simple as that.
    Chimeric’s Executive Chairman Paul Hopper said: “We are delighted to have the support of a
    leading fund manager like L1 Capital, with a strong interest in life science investing. L1’s
    commitment is testament to the quality of the Company’s clinical assets, having completed
    significant due diligence via their specialist medical consultant based in Israel prior to executing
    the placement agreement.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
2.0¢
Change
0.002(11.1%)
Mkt cap ! $17.25M
Open High Low Value Volume
1.9¢ 2.1¢ 1.9¢ $56.44K 2.801M

Buyers (Bids)

No. Vol. Price($)
5 1655923 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 1520755 2
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.